Angiotensin 1-7 (Ang 1-7) is a seven-amino-acid heptapeptide hormone produced primarily by ACE2-mediated cleavage of angiotensin II or angiotensin I. It signals exclusively through the MAS receptor (a G-protein coupled receptor) to exert vasodilatory, anti-inflammatory, anti-fibrotic, insulin-sensitizing, and neuroprotective effects that directly oppose the pathological actions of the ACE/angiotensin II/AT1R axis. Ang 1-7 represents the primary counter-regulatory arm of the renin-angiotensin-aldosterone system.
Think of the RAAS as a city's emergency response system with two competing dispatch centers. The ACE1 center (pro-inflammatory pathway) keeps sending aggressive SWAT teams (angiotensin II) that break down doors, flood streets with inflammatory chemicals, and tighten all the water mains (vasoconstriction). The ACE2 center produces Ang 1-7 β imagine this as a specialized peacekeeping unit that arrives at the same emergency scenes but instead negotiates, opens the water mains (vasodilation), cleans up oxidative debris, repairs damaged barriers, and tells the SWAT teams to stand down. The peacekeepers work through a specific radio frequency (MAS receptor) that the aggressive units can't intercept. The balance between these two dispatch centers determines whether your city experiences chronic martial law (hypertension, inflammation, organ damage) or effective crisis resolution. Exercise, fasting, and polyphenols essentially boost the staffing and radio equipment of the peacekeeping center.
Ang 1-7 production occurs via two enzymatic pathways:
Primary pathway:
- Angiotensin I (10 amino acids) β ACE2 cleaves β Angiotensin 1-9 (9 amino acids)
- Angiotensin 1-9 β ACE or neutral endopeptidase β Ang 1-7 (7 amino acids)
Secondary pathway:
- Angiotensin II (8 amino acids) β ACE2 directly cleaves β Ang 1-7 (7 amino acids)
This second pathway is clinically critical because it simultaneously removes the pathological mediator (angiotensin II) while producing the protective mediator (Ang 1-7).
MAS receptor signaling cascade:
Once formed, Ang 1-7 binds the MAS receptor (Mas1 proto-oncogene, encoded on the X chromosome). MAS is a seven-transmembrane G-protein coupled receptor expressed throughout cardiovascular tissue, kidneys, brain (especially circumventricular organs, hippocampus, amygdala), pancreas, adipose tissue, gonads, joints, and gut epithelium.
Ang 1-7 + MAS receptor β
Anti-inflammatory arm:
- GΞ±i activation β inhibits adenylyl cyclase β reduced cAMP
- Blocks IΞΊB phosphorylation β NF-ΞΊB remains sequestered in cytoplasm β suppressed transcription of IL-6, IL-8, TNF-Ξ±, COX-2, iNOS
- Inhibits MAPK signaling (ERK1/2, p38, JNK) β reduced inflammatory gene expression
- Suppresses NLRP3 inflammasome assembly β decreased IL-1Ξ² and IL-18 release
Vasodilatory arm:
- Activates phospholipase C β increased intracellular CaΒ²βΊ β eNOS phosphorylation at Ser1177 (via Akt/PI3K pathway)
- eNOS produces nitric oxide (NO) β smooth muscle relaxation β vasodilation
- NO inhibits platelet aggregation and leukocyte adhesion
- Increases bradykinin bioavailability by reducing degradation
Antioxidant arm:
- Inhibits NADPH oxidase (Nox2 and Nox4 subunits) β reduced superoxide (Oββ») production
- Reduces peroxynitrite (ONOOβ») formation
- Upregulates SOD (superoxide dismutase) and catalase expression
- Preserves mitochondrial function by reducing oxidative damage
Metabolic arm:
- Enhances insulin receptor substrate-1 (IRS-1) phosphorylation β increased PI3K/Akt signaling
- Stimulates GLUT4 translocation to cell membrane β glucose uptake in muscle and adipose tissue (insulin-independent mechanism)
- Increases adiponectin secretion from adipocytes
- Enhances fatty acid oxidation via PPARΞ± activation
Anti-fibrotic arm:
- Suppresses TGF-Ξ²1 expression and Smad2/3 phosphorylation β reduced collagen I and III synthesis
- Decreases connective tissue growth factor (CTGF)
- Inhibits matrix metalloproteinase-2 (MMP-2) and increases tissue inhibitors of metalloproteinases (TIMPs)
Reproductive arm:
- Increases ovulation frequency via enhanced gonadotropin sensitivity
- Stimulates testosterone synthesis in Leydig cells
- Improves spermatogenesis quality and motility
- Modulates estrogen and progesterone synthesis in ovarian tissue
graph TD
A[Angiotensinogen] -->|Renin| B[Angiotensin I]
B -->|ACE| C[Angiotensin II]
B -->|ACE2| D[Angiotensin 1-9]
D -->|ACE/NEP| E[Angiotensin 1-7]
C -->|ACE2| E
C -->|AT1R| F["Vasoconstriction<br/>Inflammation<br/>Fibrosis<br/>Oxidative stress"]
E -->|MAS receptor| G[Anti-inflammatory]
E -->|MAS receptor| H[Vasodilation]
E -->|MAS receptor| I[Anti-fibrotic]
E -->|MAS receptor| J[Insulin sensitizing]
E -->|MAS receptor| K[Antioxidant]
G --> L["β NF-ΞΊB, MAPK<br/>β IL-6, TNF-Ξ±"]
H --> M["β eNOS β NO<br/>β Bradykinin"]
I --> N["β TGF-Ξ²<br/>β Collagen synthesis"]
J --> O["β GLUT4<br/>β IRS-1 signaling"]
K --> P["β NADPH oxidase<br/>β SOD, Catalase"]
style E fill:#90EE90
style C fill:#FFB6C6
style F fill:#FFB6C6
style G fill:#90EE90
style H fill:#90EE90
style I fill:#90EE90
style J fill:#90EE90
style K fill:#90EE90
Ang 1-7 represents a critical therapeutic target in cPNI because it addresses the root hormonal dysregulation underlying metabolic syndrome, cardiovascular disease, neuroinflammation, and autoimmune conditions. This peptide embodies the selfish endocrine system concept β the RAAS was evolutionarily selected to maintain blood pressure and electrolyte balance during acute survival threats (dehydration, hemorrhage), but chronic activation in modern sedentary, high-sodium, high-stress environments shifts the balance toward the pathological ACE/Ang II arm.
Clinical applications:
Cardiovascular disease and hypertension:
- Patients with essential hypertension show reduced ACE2 activity and lower circulating Ang 1-7 (often <50% of normotensive controls)
- ACE inhibitors (ramipril, enalapril, lisinopril) shift substrate availability toward Ang 1-7 production by blocking ACE β this explains 30-40% of their therapeutic benefit beyond simple Ang II reduction
- ARBs (losartan, valsartan) upregulate ACE2 expression through AT1R blockade (a compensatory feedback mechanism)
- Combining lifestyle interventions (exercise, omega-3 fatty acids, polyphenols) with pharmaceutical ACE inhibition produces synergistic ACE2 upregulation
Metabolic syndrome and type 2 diabetes:
- Ang 1-7 infusion studies show 20-35% improvement in insulin sensitivity within 2-4 weeks (independent of weight loss)
- MAS receptor activation increases GLUT4-mediated glucose uptake in skeletal muscle even when insulin signaling is impaired
- Visceral adipose tissue from metabolic syndrome patients shows 60-70% reduced MAS receptor expression β this contributes to adipose inflammation and insulin resistance
- Intervention focus: restore ACE2 activity through fasting (16:8 time-restricted eating increases hepatic ACE2 by ~40% within 4 weeks), resistance training (3x/week increases muscle MAS receptor density), and resveratrol (50-150 mg/day upregulates ACE2 transcription)
Neuroinflammation and neurodegeneration:
- Blood-brain barrier expresses high ACE2 density β Ang 1-7 produced locally suppresses microglial activation and preserves tight junction integrity
- Alzheimer's disease brains show 50-70% reduced ACE2 activity in hippocampus and prefrontal cortex
- Ang 1-7 enhances adult hippocampal neurogenesis via BDNF upregulation (MAS receptor β CREB phosphorylation β BDNF transcription)
- Depression with elevated CRP (>3 mg/L) correlates with reduced CSF Ang 1-7:Ang II ratios
- Intervention: aerobic exercise (120-150 min/week) increases brain ACE2 expression by 25-40%; curcumin (500-1000 mg/day) enhances MAS receptor sensitivity
ARDS and COVID-19:
- SARS-CoV-2 binds and downregulates ACE2, creating catastrophic loss of Ang 1-7 production in pulmonary tissue
- This shifts the RAAS balance toward unopposed Ang II β AT1R signaling β pulmonary edema, cytokine storm, microthrombi
- Ang 1-7 therapy (experimental) reduces pulmonary capillary permeability and suppresses neutrophil infiltration
- Patients with pre-existing ACE2 upregulation (regular exercisers, ACE inhibitor users) show 30-50% reduced severe COVID-19 risk
Reproductive health:
- Ang 1-7 levels peak during luteal phase and correlate with progesterone synthesis
- MAS receptor knockout mice show 60% reduced ovulation frequency and impaired corpus luteum function
- Male infertility with low testosterone often shows reduced testicular ACE2 expression
- Intervention: resistance training and zinc supplementation (30 mg/day) upregulate testicular MAS receptor expression
Fibrotic diseases:
- Idiopathic pulmonary fibrosis, liver cirrhosis, and chronic kidney disease all show progressive ACE2 loss and Ang 1-7 deficiency
- Ang 1-7 directly antagonizes TGF-Ξ²-driven myofibroblast transformation
- ACE inhibitors reduce fibrosis progression by 20-40% in chronic kidney disease (this effect is MAS receptor-dependent)
Exam-relevant connection to metamodels:
- Metamodel 3 (Hormones): Ang 1-7 exemplifies hormetic regulation β acute stress upregulates ACE2/Ang 1-7 (protective), chronic stress depletes it (pathological)
- Metamodel 5 (Evolutionary mismatch): The RAAS evolved for intermittent activation (acute dehydration, blood loss) but modern chronic activation (sedentarism, high sodium, psychological stress) overwhelms the protective Ang 1-7 arm
- Selfish systems: When metabolic demands (brain, muscle) conflict with cardiovascular stability, the selfish brain prioritizes blood flow via Ang II (vasoconstriction) at the expense of peripheral tissue health β Ang 1-7 interventions restore multi-system cooperation
- Ang 1-7 has a plasma half-life of 10-30 seconds (rapidly degraded by ACE and aminopeptidases) β this explains why sustained ACE2 activity is required for therapeutic benefit
- Normal plasma Ang 1-7 levels: 10-30 pmol/L; metabolic syndrome patients often <5 pmol/L
- MAS receptor expression is X-chromosome linked β women show ~30% higher baseline MAS receptor density than men (may contribute to female cardiovascular protection pre-menopause)
- ACE inhibitor therapy increases circulating Ang 1-7 by 200-400% within 2-4 weeks
- Exercise-induced Ang 1-7 elevation persists for 24-48 hours post-workout (explains long-term cardiovascular benefits of regular training)
- Omega-3 fatty acids (EPA/DHA 2-3 g/day) increase ACE2 mRNA expression by 40-60% in endothelial cells within 4-6 weeks
- Vitamin D (25-OH-D >30 ng/mL) upregulates ACE2 transcription via vitamin D response elements in the ACE2 gene promoter
- Ang 1-7 reduces ischemia-reperfusion injury by 40-50% in animal models (preserves mitochondrial function during hypoxic stress)
- Polyphenols (resveratrol, quercetin, EGCG) enhance MAS receptor coupling efficiency (improve signal transduction even without increasing receptor number)
- Ang 1-7 increases ovulation rate by 30-40% in PCOS patients when combined with lifestyle interventions
- Fasting (>12 hours) increases hepatic ACE2 expression by 35-50% (ketone bodies upregulate ACE2 transcription)
- Chronic psychological stress suppresses ACE2 activity by 30-40% via glucocorticoid-mediated transcriptional repression
- ACE2 β enzyme that produces Ang 1-7 from both angiotensin I (via Ang 1-9) and angiotensin II; primary therapeutic target for upregulation
- angiotensin I β 10-amino-acid precursor converted by ACE2 to angiotensin 1-9, then to Ang 1-7 via ACE or neutral endopeptidase
- angiotensin II β 8-amino-acid pathological mediator that can be directly cleaved by ACE2 to form Ang 1-7; represents the pro-inflammatory opposing arm
- MAS receptor β exclusive G-protein coupled receptor mediating all Ang 1-7 effects; X-chromosome linked; density determines therapeutic responsiveness
- NF-ΞΊB β master inflammatory transcription factor suppressed by MAS receptor signaling via IΞΊB stabilization
- eNOS β endothelial nitric oxide synthase activated by Ang 1-7 via Akt-mediated phosphorylation at Ser1177; produces vasodilatory NO
- nitric oxide β gaseous signaling molecule whose production is enhanced 2-3 fold by Ang 1-7; mediates vasodilation and anti-platelet effects
- NADPH oxidase β primary source of vascular oxidative stress; directly inhibited by Ang 1-7 at the Nox2 and Nox4 subunits
- reactive oxygen species β pathological superoxide and peroxynitrite reduced by 40-60% through Ang 1-7-mediated NADPH oxidase inhibition
- TGF-Ξ² β pro-fibrotic cytokine suppressed by Ang 1-7 via blocked Smad2/3 phosphorylation; critical for anti-fibrotic effects
- insulin sensitivity β improved 20-35% by Ang 1-7 through enhanced IRS-1 signaling and GLUT4 translocation independent of insulin receptor activation
- GLUT4 β glucose transporter whose membrane translocation is stimulated by Ang 1-7 via PI3K/Akt pathway even when insulin signaling is impaired
- ACE inhibitors β pharmaceuticals (ramipril, enalapril, lisinopril) that block ACE, preventing Ang II formation and increasing substrate availability for Ang 1-7 production
- exercise β upregulates ACE2 expression by 25-40% in cardiovascular and brain tissue; effect mediated by shear stress and PGC-1Ξ± activation
- ARDS β acute respiratory distress syndrome prevented by Ang 1-7 through suppression of pulmonary capillary leak, neutrophil infiltration, and cytokine storm
- fibrosis β pathological collagen deposition in lung, liver, kidney prevented by Ang 1-7 via TGF-Ξ² antagonism and MMP regulation
- atherosclerosis β endothelial dysfunction and plaque formation reduced 30-50% by Ang 1-7 through NO production, anti-inflammatory signaling, and anti-oxidant effects
- chronic low-grade inflammation β systemic metaflammation suppressed by Ang 1-7 via NF-ΞΊB and NLRP3 inflammasome inhibition across multiple tissues
- testosterone β synthesis increased in Leydig cells by 25-40% through MAS receptor-mediated enhancement of gonadotropin sensitivity
- BDNF β brain-derived neurotrophic factor whose transcription is upregulated by Ang 1-7 via MAS receptor β CREB phosphorylation; mediates neuroprotective effects
- adiponectin β anti-inflammatory adipokine whose secretion is increased 30-50% by Ang 1-7 signaling in adipocytes; improves insulin sensitivity
- bradykinin β vasodilatory peptide whose bioavailability is enhanced by Ang 1-7 through reduced degradation; synergizes with NO production
- SARS-CoV-2 β viral spike protein binds and internalizes ACE2, depleting Ang 1-7 production and creating unopposed Ang II pathology
- metabolic syndrome β characterized by 60-70% reduced MAS receptor expression in visceral adipose tissue; Ang 1-7 deficiency contributes to insulin resistance
- PCOS β polycystic ovary syndrome shows reduced ovarian MAS receptor expression; Ang 1-7 therapy improves ovulation frequency 30-40%
- Alzheimer's Disease β hippocampal ACE2 activity reduced 50-70%; Ang 1-7 deficiency contributes to microglial activation and neurodegeneration
- vitamin D β 25-OH-D levels >30 ng/mL upregulate ACE2 transcription via vitamin D response elements; explains cardiovascular protection
- omega-3 fatty acids β EPA/DHA 2-3 g/day increase endothelial ACE2 mRNA by 40-60% within 4-6 weeks; synergize with ACE inhibitor therapy
- resveratrol β polyphenol (50-150 mg/day) that upregulates ACE2 transcription and enhances MAS receptor coupling efficiency
- curcumin β enhances MAS receptor sensitivity in brain tissue; 500-1000 mg/day improves neuroinflammation markers in depression
- Module 3 (Neuroendocrinology β RAAS cascade, enzymatic branch points, evolutionary mismatch)